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Validated HPLC analysis was developed in order to monitor the level of 4-fluorodeprenyl in rats. Male 
Wistar rats were intraperitoneally treated with 30mg/kg of (-)-4-fluorodeprenyl. The rats were sacri­
ficed after 5, 15, 30 and 60 min of treatment, and various tissues were isolated, such as serum, brain, 
CSF, liver, testis and lacrimal gland. Perchloric acid was given to aliquots, which were then homoge­
nized, centrifuged and the supernatants were taken. The 4-fluorodeprenyl content was determined using 
reversed-phase HPLC, based on the comparison of the calibration line of the spiked samples. The level 
of 4-fluorodeprenyl was between 0.5 and 24 ^g/g, showing maximum concentration in the brain and 
the liver after 5 min following its administration and in serum, CSF, testis, eyes and lacrimal gland after 
15 min following its administration, while a relatively high concentration was found in the liver and the 
lacrimal gland.
© 2014 Elsevier B.V. All rights reserved.
1. Introduction
Racemic deprenyl (N,a-m ethyl-N-2-propynyl-benzene-
ethanamine) was discovered and patented in 1962 by Ecsery 
et al. [1]. A n early discovery showed that the human metabolism 
of deprenyl gives amphetamine and methamphetamine as major 
metabolites. As (-)-isom ers of both amphetamine and m etham ­
phetamine have definitely less psychostimulant effect than the 
(+)-isomers, so (-)-deprenyl (selegiline) was synthesized and 
patented 3 years later [2]. The chemical structure of (-)-deprenyl 
is given in Fig. 1. The pharmacological spectrum of (-)-deprenyl 
was specified as early as in 1972 by Knoll and Magyar [3].
(-)-4-Fluorodeprenyl (IUPAC name: (-)-[1-(4-
fluorophenyl)propan-2-yl](methyl)(prop-2-yn-1-yl)amine) [4] 
is a halogenated derivative of (-)-deprenyl having essentially 
similar chemical properties and pharmacological effects. Simon 
et al. [5] studied the crystalline structure of enantiomeric 
hydrochlorides of deprenyl and that of its four derivatives (e.g. 
4-fluorodeprenyl). In all cases the CPhe-C-C-N torsion angle was 
anti-periplanar but in p-fluoro-amphetamine was gauche. The
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level of 4-fluorodeprenyl in the brain was analyzed using gas 
chromatography-mass spectrometry by Lajtha et al. [6].
Nag et al. [7] used [18F] derivatization of selegiline on the 
side-chain methyl of the isopropyl segment (Fig. 1). Brain incor­
poration and metabolism were investigated. Essentially slower 
metabolism was found than in the case of either selegiline ( -) -  
4-fluoro-deprenyl [7]. The uptake of [18F]fluorodeprenyl was the 
highest in the corpus striatum (and thalamus), while lower incorpo­
ration was found in the cortical areas of the cynomolgus monkey 
brain. These findings correspond to the distribution of MAO-B activ­
ity detected and reported earlier using [11C]deprenyl [16]. Nag 
et al. [7] determined in vivo uptake of [18F]fluoro-deprenyl by the 
brain, using positron emission tomography (PET) technique in two 
cynomolgus monkeys. The highest uptake was found in corpus stria­
tum, while a lower uptake in the thalamus and the cortex and the 
lowest uptake were found in the cerebellum. They demonstrated 
uptake selectivity for MAO-B, that is the uptake was essen­
tially inhibited by pre-treatment with selegiline (MAO-B enzyme 
specific inhibitor), but clorgyline (specific inhibitor of MAO-A 
enzyme) did not have any significant inhibitory effect. Plenevaux 
et al. [8,9] described the synthesis and analysis of racemic 4- 
[18F]fluorodeprenyl and that of ( -) -4 -[18F]fluorodeprenyl. They 
determined homogeneity of 4-[18F]fluorodeprenyl using both UV 
and radioactivity detectors. Plenevaux et al. [8,9] found very fast 
incorporation of 4-[18F]fluorodeprenyl in the brain of mice, and the 
brain offset of (-) -4 -[18F]fluorodeprenyl was faster than that of ( -  )- 
deprenyl from the brain. Brain versus blood level shows decreasing
530 Z. Pöstényi et al. / Journal of Pharmaceutical and Biomedical Analysis 102 (2015) 529-534
Fig. 1. The Chemical structure of (-)-deprenyl (top), (-)-4-fluorodeprenyl (centre) 
and [18F]fluorodeprenyl (bottom).
ratios such as 2.03,1.72 and 1.45 following 1,10 and 60 min follow­
ing injection (into the lateral tail vein of female albion mice, strain 
BNL), respectively.
Magyar’s experiments [10] found 4-fluorodeprenyl to be a 
definitely promising compound to substitute selegiline. Even 
4-fluorodeprenyl showed less potent inhibitory effect on MAO- 
B enzyme in vitro than that of selegiline but its level was 
longer-lasting in vivo. Moreover, its desalkylated metabolites (4- 
fluoroamphetamine and 4-fluoro-methamphetamine) were found 
more effective inhibitors of uptake than that of the parent com ­
pound. (-)-4-Fluorodeprenyl also shows more effective protection 
against neurodegenerative effects of the neurotoxin DSP-4 com ­
pared to that of (-)-deprenyl. Knoll et al. [11] showed that 
(-)-deprenyl and (-)-4-fluoro-deprenyl-treatm ent prevents age- 
related pigment changes in the substantia nigra. Their results 
indicated that these two drug-treated groups do not differ sig­
nificantly from each other in the number, total area and area of 
one pigment granule. Yasar et al. [12] investigated the behaviour 
of squirrel monkeys treated with (-)-4-fluorodeprenyl (10mg/kg, 
i.m.). The methamphetam ine-like discriminative stimulus required 
significantly higher doses than (-)-deprenyl (1.0-1.3 mg/kg, i.m.). 
The sexual activity of male Wistar rats (copulatory activity and 
ejaculation) was checked by using 0.25 mg/kg, s.c. treatment with 
(-)-4-fluorodeprenyl. Three of (-)-4-fluorodeprenyl-treated slug­
gish rats kept their full sexual activity by the end of a 25 months’ 
treatment. At the same time, the control Wistar rats lost their 
ejaculation ability earlier (Dallo and Knoll [13]). Lajtha et al. [6] 
found basic similarities between the metabolism of (-)-deprenyl 
and that of (-)-4-fluorodeprenyl following either central or periph­
eral administration. Knoll and Miklya [14] found that treatment 
with (-)-4-fluorodeprenyl enhanced the release of dopamine (from 
corpus striatum, substantia nigra and tuberculum olfactorium) and 
noradrenaline (from locus coeruleus), however, the (+)-enantiomer 
was more active than the (-)-form . Lajko et al. [15] investigated 
the effect of derivatization of deprenyl in 4-position with fluoride. 
This change did not only result in cell adhesion, but the chemo- 
tactic effect was also reversed. Selegiline ((-)-deprenyl) could 
result in significant (63.4%) cytotoxic effect on MM6 monocyte 
cells, its 10- 9 M possesses antiproliferative character (88%). Sim ­
ilar antiproliferative effects were observed in the case of the two 
enantiomers of 10-6 M 4-fluorodeprenyl ((-)-isom er 77.9% and (+)- 
isomer 85.9%).
Our aim was to determine pharmacokinetics of 4- 
fluorodeprenyl using rats including serum, brain, CSF, liver, 
testis and lacrimal gland.
2. Materials and methods
2.1. Chemicals and reagents
Acetonitrile, sodium 1-decanesulfonate, citric acid monohy­
drate were purchased from Sigm a-Aldrich (Schnelldorf, Germany), 
perchloric acid (PCA, 70%) and sodium phosphate dibasic dihydrate 
were purchased from Merck (Darmstadt, Germany) in the best 
available purity. Phosphoric acid 85% was bought from Finomve­
gyszer Szövetkezet (Budapest, Hungary). Selegiline ((-)-deprenyl 
hydrochloride) and (-)-4-fluorodeprenyl hydrochloride were the 
kind gifts of Chinoin Pharmaceutical Company (Budapest, Hungary 
-  its name is now Chinoin-Sanofi). The water used was Type 1 ultra­
pure water prepared in our laboratory (Direct-Q3, Merck Millipore, 
Darmstadt, Germany).
2.2. Animals
Male Wistar rats, weighing 200-205 g were supplied by 
Toxicoop (Budapest, Hungary). All experiments conformed to 
86/509/EEC regulation on the well-being of experimental animals, 
and the experimental protocol was approved by the local ethical 
committee (permission number: 1810/003/2004 ANTSZ, Budapest, 
Hungary).
Rats (n = 4, in each groups) were intraperitoneally (i.p.) treated 
with 30 mg/kg (-)-4-fluorodeprenyl hydrochloride freshly dis­
solved in double-distilled water. The rats were sacrificed after 5, 
15,30 and 60 min of treatment and the following tissues were iso­
lated: serum, brain, CSF, liver, testis and lacrimal gland. The samples 
were stored at - 8 0 0C.
2.3. Instruments and chromatographic conditions
The chromatographic analysis was performed with a JASCO 
(Tokyo, Japan) system consisting of DG-2080-54 Degasser, PU-1580 
HPLC Pump, AS-2057 Plus Autosampler (maintained at 4 0C), UV- 
975 UV/Vis Detector (operated at 265 nm) and JMBS Hercule 2000 
Chromatography Interface (Le Fontanil, France). Chromatograms 
were electronically stored and evaluated using Borwin 1.50 Chro­
matography Software (JMBS, Le Fontanil, France). The separation 
was done using a (4.6 mm x 250 mm, 5 |xm) Zorbax Rx-C18 octade- 
cyl silica column (Agilent Technologies, Santa Clara, CA, USA; 
supplied by Kromat Kft., Budapest, Hungary). The mobile phase 
consisted of 730 ml of buffer [10g Na2HPO4 2H2O + 10g citric 
acid + 10 mg Na2EDTA + 25 mg sodium 1-decanesulfonate dissolved 
in purified water, pH was adjusted to 3.7 with phosphoric acid] and 
270 ml acetonitrile (27%). The mobile phase was filtered through a 
0.45 |xm nylon membrane filter (Agilent Technologies) and then 
sonicated for 5 min using ultrasonic bath (Branson 2510). The flow 
rate of the mobile phase was 1 ml/min, the temperature of the 
column was 3 5 0C and the volume of injection was 40 |xl.
2.4. Preparation of stock and standard solutions
Stock solution of (-)-4-fluorodeprenyl hydrochloride 
(1000 |xg/ml) was prepared by dissolving the drug in double- 
distilled water and further diluted with double-distilled water to 
obtain the different working standard solutions ranging from 0.2 
to 50 |xg/ml. The stock solution was diluted to 5, 10 and 50 |xg/ml 
for the validation measurements.
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2.5. Preparation of biological samples
Dissected tissues from either untreated or treated animals were 
homogenized by an Ultra Turrax T25 Janke-Kunkel homogenizer 
(IKA Labortechnik, Staufen, Germany) at 20,000 rpm/min for 30 s 
at room temperature in 0.3 M perchloric acid. The homogenates 
were centrifuged in an Eppendorf centrifuge (A. Hettich, Tuttlingen, 
Germany) with 14,000 rpm for 20 min at 4 °C.The supernatant was 
collected for the further procedure.
2.6. Method validation
2.6.1. Specificity
To determine the specificity of the method, control serum sam­
ples, serum spiked with known amounts of the drug (10 |ag/ml) and 
serum samples from W istar rats after the i.p. dose of drug were 
analyzed.
2.6.2. Peak purity
The peak purity of (-)-4-fluorodeprenyl was determined by 
comparing the spectrum at three different regions of the spot i.e. 
peak start, peak apex and peak end (not shown here).
2.6.3. Linearity
The linearity was evaluated in the concentration range of 
0.2-50 |ag/ml at ten different levels of standard solutions (0.2, 0.5, 
0.7, 1, 2, 5, 7, 10, 20 and 50 |ag/ml). Blank biological samples were 
spiked with standard solutions of 4-fluorodeprenyl at nine differ­
ent levels (0.5, 0.7, 1, 2, 5, 7, 10, 20 and 50 |ag/ml). Linearity was 
determined by the calculation of a regression linear line from the 
peak area versus concentrations of standard solutions and spiked 
samples using linear least squares methodology.
2.6.4. Limit of detection and limit of quantification
The limit of detection (LOD) is defined as the concentration of 
the analyte giving a signal-to noise-ratio of 3:1. The limit of quan­
titation (LOQ) of the assay is the smallest concentration that can be 
quantitated reliably with a specified level of accuracy and precision, 
giving a signal-to noise-ratio of 10:1.
2.6.5. Precision
The intra- and interday precision of the measurement were 
determined by percentage relative standard deviation (RSD). The 
intra- and inter-assay precisions were evaluated by analyzing the 
standard samples at 5, 10 and 50 |ag/ml concentration level of
Fig. 2. 4-Fluorodeprenyl calibration lines: standard (y = 4462.7x + 0, R2 = 0.9998), 
spiked serum (y = 4626.1x + 0, R2 = 0.9998), spiked brain(y = 4267.9x + 0, R2 = 0.9991).
(-)-4-fluorodeprenyl. For the intraday validation, six replicates 
of the standard samples were analyzed on the same day. For the 
interday validation, six replicates of the serum samples were 
analyzed on three different days. The results were expressed as 
RSD% of the measurements.
2.6.6. Robustness
Robustness was determined by changing the mobile phase pH 
to 3.4 and 4.0 and the concentration of acetonitrile in the mobile 
phase to 22 and 32%.
3. Results
The relation between peak area and concentration was 
linear (R2 >0.999; RSD 0.01) within the concentration range 
(0.5-50 |ag/ml) in case of standard solution and also in the spiked 
serum and brain samples (Fig. 2a-c). Following the injection of 
blank samples there were no interfering peaks observed at the 
expected retention time of (-)-4-fluorodeprenyl which would dis­
turb the determination. The precision studies indicated that the 
developed HPLC method was reproducible and the results are 
shown in Table 1. The % of RSD of robustness tested under different 
modified conditions is given in Table 2, indicating that the current 
method is robust. LOD and LOQ of (-)-4-fluorodeprenyl were 0.2 
and 0.5 |ag/ml, respectively.
The distribution of 4-fluorodeprenyl in the rat was analyzed 
using reversed-phase HPLC-UV. The intact (-)-4-fluorodeprenyl
Table 1
Intraday and interday reproduction of (-)-4-fluorodeprenyl determination.
Concentration added (p,g/ml) Area ±SD Concentration found (p,g/ml ±SD) RSD (%) Recovery (% ±SD) n
Intraday
5 22,672 ± 249 4.89 ± 0.05 1.09 98.06 ± 1.0 6
10 45,313 ± 199 9.99 ± 0.04 0.44 99.98 ± 0.43 6
50 235,827 ± 399 50.30 ± 0.08 0.17 100.61 ± 0.17 6
Interday
5 23,158 ± 716 5.00 ± 0.15 3.08 100.06 ± 3.08 18
10 45,508 ± 355 10.00 ± 0.07 0.72 100.06 ± 0.72 18
50 234,274 ±3196 49.98 ± 0.68 1.36 99.95 ± 1.36 18
Table 2
Robustness of (-)-4-fluorodeprenyl determination.
Robustness Acetonitrile % ofthe mobile phase pH of the mobile phase
22% 27% 32% 3.4 3.7 4.0
Retention time (min) ± SD 14.594 ±0.05 12.791 ±0.02 6.074 ±0.01 12.322 ±0.02 12.755± 0.02 14.516 ±0.03
RSD% 0.39 0.21 0.23 0.16 0.16 0.25
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Fig. 3. (A-C) HPLC of rat serum samples (A: blank serum, B: spiked serum, C: serum sample from treated rat). The peak of (-)-4-fluorodeprenyl is marked with an arrow.
gave a distinct, well-resolved peak from the background from rat 
serum (Fig. 3A -C), brain (Fig. 4A -C), lacrimal gland (Fig. 5A-C), CSF, 
liver, testis and eyes (not shown here).
The tissue level of (-)-4-fluorodeprenyl was surprisingly high in 
the lacrimal gland following 15 min of i.p. injection and in the liver 
following 5 min of i.p. injection, and (-)-4-fluorodeprenyl showed 
continuous decline as shown in Table 3 .
Comparing the level of (-)-4-fluorodeprenyl in the brain and 
CSF, it was significantly higher in the brain.
4. Discussion
Drug monitoring and biodistribution studies need a selective, 
simple and reproducible analysis. The developed method met these 
requirements, and it was validated.
The fast onset of 4-fluorodeprenyl can be explained by its defi­
nite lipophilicity. Our experiments used male W istar rats that were 
subjected to intraperitoneal injections using (-)-4-fluorodeprenyl. 
The results mirrored similar results, such as fast onset of drug level. 
A surprisingly high content (related to the serum) was found in the 
lacrimal gland, liver and brain of the rats. Moderately slow offset 
took place in each part (organs and tissues) of the rats. The high 
level of (-)-4-fluorodeprenyl in the brain can be explained by its 
specific binding to the brain MAO-B enzyme [7].
The dose of (-)-deprenyl (selegiline) and its analogues depends 
on their indications. For classical human indication (parkinson­
ism), a dose of 10 mg/day is recommended. This dose corresponds 
to a daily administration of 0.10-0.20 mg/kg. As the indication of 
selegiline became wider, higher doses are also recommended in the 
case of deprenyl and its analogues used for the treatment of major
Fig. 4. (A-C) HPLC of rat brain samples (A: blank brain, B: spiked brain, C: brain sample from treated rat). The peak of (-)-4-fluorodeprenyl is marked with an arrow.
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Fig. 5. (A-C) HPLC of rat lacrimal gland samples (A: blank lacrimal gland, B: spiked lacrimal gland, C: lacrimal gland from treated rat). The peak of (-)-4-fluorodeprenyl is 
marked with an arrow.
Table 3
(-)-4-fluorodeprenyl content of various body fluids and tissues of rats following 30mg/kg i.p. injection, n = 4.
Samples Content ± SD
5 min 15 min 30 min 60 min
Serum (pg/ml) 3.74 ± 0.12 5.53 ± 1.08 2.95 ± 0.68 1.72 ± 0.34
Brain (pg/g) 7.17 ± 0.93 4.66 ± 1.5 4.208 ± 1.71 1.89 ± 0.59
CSF (pg/ml) 1.11 ± 0.21 1.80 ± 0.44 1.22 ± 0.08 0.66 ± 0.14
Testis (pg/g) 4.33 ± 0.66 5.80 ± 1.63 5.14 ± 1.41 3.44 ± 1.18
Liver (pg/g) 23.13 ± 6.55 18.03 ± 3.26 9.68 ± 1.99 7.06 ± 1.27
Eyes (pg/g) 1.70 ± 0.24 1.86 ± 0.27 1.65 ± 0.44 1.19 ± 0.15
Lacrimal glands (pg/g) 10.56 ± 0.69 15.82 ± 5.78 9.77 ± 4.39 8.17 ± 2.79
depression using a transdermal patch (Emsam Patch). In veteri­
nary medicine, a high dose of deprenyl is used for the treatment 
of the symptoms of Cushing’s disease and cognitive dysfunction 
(Canine Cognitive Dysfunction). Low toxicity of (-)-deprenyl and 
its analogues may allow even higher doses of administration.
Quantitative analysis of (-)-deprenyl and (-)-4-fluorodeprenyl 
is possible using a wide choice of various analytical methods, 
such as mass spectrometry, radioactivity detectors, gas chro- 
matography/mass spectrometry, HPLC/UV, HPLC/EC and HPLC/MS. 
HPLC is a generally used method, and HPLC with ampero- 
metric/electrochemical detection is quite sensitive, it can be 
recommended for quantitative determination of lower level of ( -) -  
deprenyl and its analogues.
HPLC separation combined with a UV detector is the utmost 
simply manageable and inexpensive method for the quantitative 
analysis of (-)-deprenyl and its para-substituted analogues in the 
range of drug levels over 0.5 pg/ml in body fluids and tissues. 
Successful use HPLC/UV is one of the important novelties of this 
paper.
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